PubAg

Main content area

Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis

Author:
Qian, Kai, Xu, Jie, Wan, Heng, Fu, Fangyong, Lu, Jingbo, Lin, Zhiqi, Liu, Zhengjun, Liu, Hao
Source:
Gene 2015 v.569 pp. 173-181
ISSN:
0378-1119
Subject:
alleles, confidence interval, fibrinolysis, heterozygosity, meta-analysis, models, nationalities and ethnic groups, odds ratio, patients, risk, single nucleotide polymorphism, thrombin, thrombosis
Abstract:
Reported studies have showed that Thrombin Activatable Fibrinolysis Inhibitor (TAFI) may be associated with an increased risk of venous thromboembolism. But the relation of VT with TAFI gene SNPs could not be clearly demonstrated. Thus, we conducted a meta-analysis to analyze the associations between three TAFI variants −438G/A, 505G/A and 1040C/T and the risk of venous thrombosis.We carried out a systematic search to obtain all the eligible studies published before 30th October 2014. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were computed to assess the association.13 eligible studies were enrolled including 2321 patients and 2464 controls. There was a significant association between 505G/A and the risk of VTD under all models except recessive model (G vs. A: OR=1.13, 95% CI: 1.02, 1.26; GG vs. AA:OR=1.47, 95% CI: 1.14, 1.88; GA vs. AA: OR=1.36, 95% CI: 1.06, 1.73; GG+GA vs. AA: OR=1.41, 95% CI: 1.12, 1.77). Similarly, obvious relationship was observed in subgroup analyses in light of type of disease and ethnicity. Likewise, for 1040C/T variant, significant associations were identified under homozygote, heterozygote and dominant models (CC vs. TT: OR=1.65, 95% CI: 1.06, 2.59; CT vs. TT: OR=1.55, 95% CI: 1.19, 2.03; CC+CT vs. TT: OR=1.55, 95% CI: 1.20, 2.00). Sub-analysis presented significant associations in non-CVT and non-Asian group under homozygote, heterozygote, and dominant models and CVT group in recessive model.This meta-analysis showed that −438G/A variant was not associated with the incidence of venous thrombosis. But in non-Asian populations, G allele and GG genotype of 505G/A may increase the risk of venous thrombosis diseases. GG genotype of 505G/A and one C carrier (CC and CT) of 1040C/T gave rise to the development of venous thrombosis diseases except CVT. Additionally, the heterozygote CT may be a potential contributing factor of gene effect in venous thrombosis.
Agid:
5524940